Gelonghui, March 7 | Jilin Aodong (000623.SZ) said on the investor interactive platform that the company currently has 616 drug production approval numbers, a total of 206 products have been included in the national medical insurance catalogue, and a total of 91 products have entered the national essential drugs catalogue. The pediatric drug catalogue categories include Pediatric Chai Gui Antipyretic Oral Liquid and Sports Digestive Oral Liquid. As a national exclusive patented product (Patent No.: ZL200410010761.1), Pediatric Chai Gui Antipyretic Oral Liquid has developed into a core variety after years of cultivation. The company insists on continuing to be deeply involved in the field of pediatrics, increasing investment in scientific research and academic promotion, using pediatric Chai Gui antipyretic oral liquid as the main product, speeding up the development of key customer chain markets, standardizing the management of private hospitals and prescription channels outside hospitals, strengthening academic guidance, and achieving rapid growth. Chai Gui Antipyretic Oral Liquid for children has the advantages of high cure rate, low recurrence rate, short treatment cycle, stable fever relief and no rebound, and has quickly become a first-line medication for pediatric respiratory diseases. The company has formed a successful empirical development model in the process of creating Chai Gui Antipyretic Oral Liquid for Children as the core product, which can help other varieties with growth potential to achieve rapid development. The company focuses on the field of pediatrics to create superior varieties in the clinical field of antipyretic and cough relief, such as pediatric Chai Gui antipyretic oral liquid and Ling Bei cough syrup, to form a rich pediatric variety group, which is gradually growing and expanding.